

## Special Issue

# Beta Amyloid: Synaptic Regulation and Dysregulation

### Message from the Guest Editors

The approval of Aducanumab and the confirmation of the anti-amyloid strategy against Alzheimer's disease strongly support the need for new research focused on the role of beta-amyloid in central nervous system (CNS) homeostasis. Antibody-related treatment, alongside an efficacy dispute, provokes interesting side effects such as "amyloid-related imaging abnormalities" (ARIA) and vascular consequences. Other side effects occurring at the synaptic level could be masked by disease derangement. In our mind, all scientific reports (positive and negative results) in this field are fundamental to improve the efficacy and sustainability of this therapeutic approach. This Special Issue highlights the most recent research based on functional or pathological effects of beta-amyloid and/or neutralizing antibodies on CNS homeostasis.

beta amyloid  
aducanumab  
amyloid neutralizing antibodies  
ARIA  
Alzheimer's disease  
synaptic modulation

---

### Guest Editors

Dr. Massimo Grilli  
Department of Pharmacy, University of Genova, 16148 Genoa, Italy  
Dr. Guendalina Olivero  
Department of Pharmacy, University of Genova, 16148 Genoa, Italy

---

### Deadline for manuscript submissions

closed (30 November 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/94128](https://mdpi.com/si/94128)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).